Form 4: Simeon George Reports Acquisition of CRISPR Therapeutics Shares Through Indirect Holdings

Director Simeon George reports the acquisition of CRISPR Therapeutics shares through several investment partnerships, disclaiming beneficial ownership except to the extent of his pecuniary interest.

Summary

• Simeon George, a director of CRISPR Therapeutics AG, reported the acquisition of common shares on February 27, 2024.
• The shares were acquired indirectly through several entities: SR One Capital Fund II Aggregator, LP; SR One Capital Opportunities Fund I, LP; and AMZL, LP.
• A total of 63,177 shares were acquired through SR One Capital Fund II Aggregator, 216,578 shares through SR One Capital Opportunities Fund I, and 769,196 shares through AMZL, all at a price of $71.50 per share.
• George disclaims beneficial ownership of the shares except to the extent of his pecuniary interest in the investment partnerships.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating share acquisition by a director, which can be interpreted as a positive sign, but the director disclaims full beneficial ownership.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for insights into management's perspective on the company's prospects. The acquisition of shares, even indirectly, can be seen as a positive signal.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder confidence.

Key Dates